X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (56) 56
humans (53) 53
cardiac & cardiovascular systems (48) 48
female (34) 34
male (34) 34
cardiovascular (31) 31
abridged index medicus (26) 26
middle aged (25) 25
internal medicine (22) 22
aged (21) 21
heart failure (20) 20
cardiomyopathy (19) 19
chemotherapy (15) 15
amyloidosis (14) 14
care and treatment (14) 14
heart diseases (14) 14
cancer (12) 12
heart (12) 12
mortality (12) 12
adult (10) 10
drug therapy (10) 10
retrospective studies (10) 10
antineoplastic agents - adverse effects (9) 9
congestive-heart-failure (9) 9
diagnosis (9) 9
echocardiography (9) 9
insulin resistance (9) 9
medicine, general & internal (9) 9
transthyretin (9) 9
analysis (8) 8
cardiology (8) 8
cardiotoxicity (8) 8
health aspects (8) 8
heart-failure (8) 8
patients (8) 8
prognosis (8) 8
transplantation (8) 8
cardiology and cardiovascular medicine (7) 7
medical colleges (7) 7
neoplasms - drug therapy (7) 7
treatment outcome (7) 7
ventricular dysfunction, left - chemically induced (7) 7
aged, 80 and over (6) 6
amyloid (6) 6
article (6) 6
breast cancer (6) 6
cardiac amyloidosis (6) 6
disease (6) 6
follow-up studies (6) 6
glucose (6) 6
hypertension (6) 6
peripheral vascular disease (6) 6
surgery (6) 6
animals (5) 5
antineoplastic agents - therapeutic use (5) 5
cardiac patients (5) 5
cardiovascular diseases (5) 5
diabetes (5) 5
heart failure - drug therapy (5) 5
hematology (5) 5
insulin (5) 5
management (5) 5
oncology (5) 5
risk (5) 5
risk factors (5) 5
rodents (5) 5
stem-cell transplantation (5) 5
therapy (5) 5
trastuzumab (5) 5
aging (4) 4
al amyloidosis (4) 4
amyloidosis - complications (4) 4
amyloidosis - drug therapy (4) 4
anthracyclines - adverse effects (4) 4
breast-cancer (4) 4
cardiovascular disease (4) 4
clinical trials (4) 4
dextrose (4) 4
heart attacks (4) 4
heart diseases - chemically induced (4) 4
heart failure - chemically induced (4) 4
heart transplantation (4) 4
high-dose chemotherapy (4) 4
left-ventricular dysfunction (4) 4
medicine & public health (4) 4
mutation (4) 4
natriuretic peptide (4) 4
patient outcomes (4) 4
phenotype (4) 4
polyneuropathy (4) 4
prevalence (4) 4
stem cells (4) 4
studies (4) 4
survival (4) 4
survival rate - trends (4) 4
systemic amyloidosis (4) 4
usage (4) 4
adjuvant chemotherapy (3) 3
adrenergic beta-antagonists - therapeutic use (3) 3
amyloid - metabolism (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 10, pp. A618 - A618
  Development of cardiovascular collapse with refractory high-grade fever suggested massive catecholamine release from hemorrhage into the tumor. [...]we... 
Cardiovascular | Internal Medicine | Heart | Palpitation | Headaches | Cardiac arrhythmia | Heart attacks
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2008, Volume 51, Issue 2, pp. 93 - 102
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 11, pp. 2411 - 2411
  Advanced PAH therapies such as sildenafil are contraindicated in this setting because they would increase blood flow to the left heart and augment... 
Cardiovascular | Internal Medicine | CARDIAC & CARDIOVASCULAR SYSTEMS | Methamphetamines
Journal Article
Circulation, ISSN 0009-7322, 04/2016, Volume 133, Issue 15, pp. e598 - e598
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2016, Volume 22, Issue 5, pp. 547 - 556
Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of malignancies, but it causes a dose-related cardiotoxicity that can... 
MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE STRESS | RISK-FACTORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DEXRAZOXANE | INDUCED CARDIOMYOPATHY | MATURATION | MUSCLE GENE-EXPRESSION | CELL BIOLOGY | CHILDHOOD-CANCER | INHIBITION | ANTHRACYCLINE-INDUCED CARDIOTOXICITY | CONGESTIVE-HEART-FAILURE | Mitochondria, Heart - metabolism | Reactive Oxygen Species - metabolism | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Calcium - metabolism | Humans | Middle Aged | Transcriptome | Antibiotics, Antineoplastic - adverse effects | Mitochondria, Heart - drug effects | Membrane Potential, Mitochondrial - drug effects | Flow Cytometry | Adult | Female | Real-Time Polymerase Chain Reaction | Cardiotoxicity - genetics | DNA Damage - drug effects | Cell Survival - drug effects | Disease Susceptibility | Heart Failure - genetics | Breast Neoplasms - drug therapy | Myocytes, Cardiac - drug effects | Fluorescent Antibody Technique | Myocytes, Cardiac - metabolism | Aged | Polymorphism, Single Nucleotide | Oxidative Stress - drug effects | Induced Pluripotent Stem Cells | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Heart Failure - chemically induced | Complications and side effects | Patient outcomes | Stem cells | Development and progression | Breast cancer | Transplantation | Cardiovascular diseases | Drug therapy | Doxorubicin | Methods | Heart failure | Chemotherapy | Toxicity | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 11, pp. 1007 - 1016
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2013, Volume 110, Issue 24, pp. 9992 - 9997
The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, underlies a large number of human degenerative diseases. Cardiac... 
Aggregation | Exchange rates | Molecules | Familial amyloidosis | Ligands | Cardiomyopathies | Amyloids | Kinetics | Monomers | Binding sites | Drug design | Crystal structure | POLYNEUROPATHY | PROTEIN | drug design | MULTIDISCIPLINARY SCIENCES | CARDIAC AMYLOIDOSIS | VARIANT | TRANSPLANTATION | HEART | PLASMA | DISSOCIATION | DISEASE | crystal structure | AFRICAN-AMERICANS | Amyloidosis - prevention & control | Benzoxazoles - pharmacology | Prealbumin - genetics | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Rats, Wistar | Area Under Curve | Benzoates - chemistry | Humans | Benzoxazoles - metabolism | Cardiomyopathies - prevention & control | Crystallography, X-Ray | Dose-Response Relationship, Drug | Cardiomyopathies - genetics | Pyrazoles - chemistry | Amyloid - metabolism | MCF-7 Cells | Amyloidosis - genetics | Molecular Structure | Prealbumin - chemistry | Pyrazoles - pharmacokinetics | Protein Structure, Tertiary | Amyloid - antagonists & inhibitors | Amyloid - genetics | Cell Line | Cell Survival - drug effects | Models, Molecular | Rats | Mice, Inbred ICR | Animals | Prealbumin - metabolism | Cardiomyopathies - metabolism | Protein Stability - drug effects | Cell Line, Tumor | Protein Binding | Mice | HeLa Cells | Mutation | Amyloidosis - metabolism | Benzoates - pharmacokinetics | Benzoxazoles - pharmacokinetics | Proteins | Heart | African Americans | Cytotoxicity | Cells | Index Medicus | Biological Sciences
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9880, pp. 1813 - 1813
  [...]as the authors point out, the signal towards lower mortality should be deemed supportive of safety but not long-term efficacy since the study was... 
Internal Medicine | TRIAL | MEDICINE, GENERAL & INTERNAL | DYSPNEA | Female | Male | Relaxin - therapeutic use | Humans | Heart Failure - drug therapy | Clinical trials | Drug therapy | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2010, Volume 56, Issue 20, pp. 1644 - 1650
Objectives: The purpose of this study was to examine treatment practices for cancer therapy-associated decreased left ventricular ejection fraction (LVEF)... 
Heart failure | Left ventricular dysfunction | Anthracyclines | Chemotherapy | Cancer | ADJUVANT CHEMOTHERAPY | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | TRASTUZUMAB | ADULTS | left ventricular dysfunction | chemotherapy | HER2-POSITIVE BREAST-CANCER | TRIAL COMPARING DOXORUBICIN | LYMPHOMA | cancer | anthracyclines | CONGESTIVE-HEART-FAILURE | HER2 | PLUS | Anthracyclines - adverse effects | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Heart Ventricles - diagnostic imaging | Ventricular Dysfunction, Left - chemically induced | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Antineoplastic Agents - adverse effects | Ultrasonography | Adult | Female | Retrospective Studies | Adrenergic beta-Antagonists - therapeutic use | Risk Factors | Stroke Volume - drug effects | Ventricular Dysfunction, Left - physiopathology | Neoplasms - drug therapy | Ventricular Dysfunction, Left - drug therapy | Heart Ventricles - physiopathology | Aged | Anthracyclines - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Trastuzumab | Breast cancer | Heart attacks | Drug therapy | Cancer therapies | Beta blockers | Leukemia | Index Medicus | Abridged Index Medicus | Angiotensin receptors
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2016, Volume 68, Issue 2, pp. 161 - 172
Journal Article